CENTURY THERAPEUTICS INC (IPSC)
US15673T1007 - Common Stock
Overall IPSC gets a fundamental rating of 3 out of 10. We evaluated IPSC against 561 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for IPSC as it has an excellent financial health rating, but there are worries on the profitability. IPSC does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
IPSC had negative earnings in the past year.
In the past year IPSC has reported a negative cash flow from operations.
IPSC had negative earnings in each of the past 5 years.
IPSC had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -33.42%, IPSC is in the better half of the industry, outperforming 64.14% of the companies in the same industry.
IPSC has a Return On Equity of -66.38%. This is comparable to the rest of the industry: IPSC outperforms 57.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.42% | ||
| ROE | -66.38% | ||
| ROIC | N/A |
ROA(3y)-28.9%
ROA(5y)N/A
ROE(3y)-47.14%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for IPSC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IPSC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IPSC has been increased compared to 1 year ago.
IPSC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
IPSC has an Altman-Z score of -2.94. This is a bad value and indicates that IPSC is not financially healthy and even has some risk of bankruptcy.
IPSC's Altman-Z score of -2.94 is in line compared to the rest of the industry. IPSC outperforms 47.57% of its industry peers.
There is no outstanding debt for IPSC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.94 |
ROIC/WACCN/A
WACC10.88%
2.3 Liquidity
A Current Ratio of 10.39 indicates that IPSC has no problem at all paying its short term obligations.
IPSC has a Current ratio of 10.39. This is amongst the best in the industry. IPSC outperforms 82.52% of its industry peers.
A Quick Ratio of 10.39 indicates that IPSC has no problem at all paying its short term obligations.
The Quick ratio of IPSC (10.39) is better than 82.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.39 | ||
| Quick Ratio | 10.39 |
3. Growth
3.1 Past
IPSC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.53%, which is quite good.
The Revenue has been growing slightly by 7.83% in the past year.
EPS 1Y (TTM)15.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.73%
Revenue 1Y (TTM)7.83%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%434.46%
3.2 Future
Based on estimates for the next years, IPSC will show a small growth in Earnings Per Share. The EPS will grow by 7.41% on average per year.
The Revenue is expected to grow by 97.75% on average over the next years. This is a very strong growth
EPS Next Y27.64%
EPS Next 2Y18.77%
EPS Next 3Y4.75%
EPS Next 5Y7.41%
Revenue Next Year89.44%
Revenue Next 2Y58.04%
Revenue Next 3Y1.52%
Revenue Next 5Y97.75%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
IPSC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IPSC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.77%
EPS Next 3Y4.75%
5. Dividend
5.1 Amount
No dividends for IPSC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CENTURY THERAPEUTICS INC
NASDAQ:IPSC (1/8/2025, 8:09:56 PM)
After market: 1.0719 +0 (+0.18%)1.07
+0.01 (+0.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners58.77%
Inst Owner Change0%
Ins Owners3.08%
Ins Owner Change-0.36%
Market Cap90.98M
Analysts84.62
Price Target9.86 (821.5%)
Short Float %4.49%
Short Ratio4.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.14%
Min EPS beat(2)19.03%
Max EPS beat(2)19.26%
EPS beat(4)3
Avg EPS beat(4)8.86%
Min EPS beat(4)-14.97%
Max EPS beat(4)19.26%
EPS beat(8)5
Avg EPS beat(8)4.89%
EPS beat(12)7
Avg EPS beat(12)4.74%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-61.27%
Min Revenue beat(2)-61.68%
Max Revenue beat(2)-60.86%
Revenue beat(4)0
Avg Revenue beat(4)-60.45%
Min Revenue beat(4)-85.7%
Max Revenue beat(4)-33.57%
Revenue beat(8)1
Avg Revenue beat(8)-58.27%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.9%
EPS NY rev (1m)0%
EPS NY rev (3m)8.49%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.4%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)-0.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 33.89 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.46 | ||
| P/tB | 0.58 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.85
EYN/A
EPS(NY)-1.35
Fwd EYN/A
FCF(TTM)-1.33
FCFYN/A
OCF(TTM)-1.32
OCFYN/A
SpS0.03
BVpS2.3
TBVpS1.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.42% | ||
| ROE | -66.38% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-28.9%
ROA(5y)N/A
ROE(3y)-47.14%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 10.39 | ||
| Quick Ratio | 10.39 | ||
| Altman-Z | -2.94 |
F-Score5
WACC10.88%
ROIC/WACCN/A
Cap/Depr(3y)555.69%
Cap/Depr(5y)738.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.73%
EPS Next Y27.64%
EPS Next 2Y18.77%
EPS Next 3Y4.75%
EPS Next 5Y7.41%
Revenue 1Y (TTM)7.83%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%434.46%
Revenue Next Year89.44%
Revenue Next 2Y58.04%
Revenue Next 3Y1.52%
Revenue Next 5Y97.75%
EBIT growth 1Y-2.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-297.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-989.29%
OCF growth 3YN/A
OCF growth 5YN/A